Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
|Articles|April 24, 2018
News You Should Know: 3 Takeaways from Top Managed Care Articles April
Author(s)John Schieszer
Advertisement
News You Should Know April 2018
Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.
Advertisement
Related to this article
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility.
New data from Sutter Health suggest the real gap in GLP-1 access is physician awareness, not insurance coverage — and fixing it closed outcome disparities across every racial and ethnic group.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
3
For bronchiectasis, a new era of guideline-guided care | CHEST 2026
4
Now is the time to get ready for 2027 changes in prior authorization, MA Star Ratings and others in federal healthcare law and regulations
5